% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Tichanek:282684,
      author       = {F. Tichanek and A. Försti$^*$ and O. Hemminki and A.
                      Hemminki and K. Hemminki$^*$},
      title        = {{S}teady survival improvements in soft tissue and bone
                      sarcoma in the {N}ordic countries through 50 years.},
      journal      = {Cancer epidemiology},
      volume       = {92},
      issn         = {1877-7821},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-01830},
      pages        = {102449},
      year         = {2024},
      note         = {#LA:C020# / 2024 Oct;92:102449},
      abstract     = {Sarcomas are rare cancers with many subtypes in soft
                      tissues, bone and cartilage. International survival trends
                      in these cancers are not well known. We present 50-year
                      survival trends for soft tissue sarcoma (STS) and bone
                      sarcoma (BS) in Denmark (DK), Finland (FI), Norway (NO) and
                      Sweden (SE).Relative 1-, 5/1 conditional- and 5-year
                      survival data were obtained from the NORDCAN database for
                      years 1971-20. We additionally estimated annual changes in
                      survival rates and determined significant break points.In
                      the last period, 2016-20, 5-year survival in STS was best
                      for NO men $(74.6\%)$ and FI women $(71.1\%).$ For the rarer
                      BS, survival rates for SE men $(72.0\%)$ and DK women
                      $(71.1\%)$ were best. Survival in BS was lower than that in
                      STS in 1971-75 and the difference remained in 2016-20 for
                      men, but for women the rates were almost equal. Sex- and
                      country-specific differences in survival in STS were small.
                      The 50-year improvement in 5-year survival in STS was
                      highest in NO men, 34.0 $\%$ units and FI women, 30.0 $\%$
                      units. The highest improvements in BS were in SE men 26.2
                      $\%$ units and in FI women 29.2 $\%$ units.The steady
                      development in survival over the half century suggests
                      contribution by stepwise improvements in diagnostics,
                      treatment and care. The $10-15\%$ mortality in the first
                      year probably indicates diagnostic delays which could be
                      improved by organizing patient pathways for aggressive rare
                      diseases. Early diagnosis would also reduce metastatic
                      disease and breakthroughs in treatment are a current
                      challenge.},
      keywords     = {Conditional survival (Other) / Diagnostics (Other) /
                      Incidence (Other) / Relative survival (Other) / Treatment
                      (Other)},
      cin          = {B062 / HD01 / C020},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37679266},
      doi          = {10.1016/j.canep.2023.102449},
      url          = {https://inrepo02.dkfz.de/record/282684},
}